Search
Search Results
##search.searchResults.foundPlural##
-
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2600PDF: 1655HTML: 714 -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3810PDF: 1354HTML: 2172Fig.1: 246Fig. 2: 238 -
A MULTICENTER ICET-A STUDY ON AGE AT MENARCHE AND MENSTRUAL CYCLES IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA (TDT) WHO STARTED EARLY CHELATION THERAPY WITH DIFFERENT CHELATING AGENTS. Age at menarche and menstrual cycles in patients with transfusion-dependent thalassemia.
878PDF: 591HTML: 186 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3265PDF: 1678HTML: 370 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2835PDF: 879HTML: 15030Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 349 -
-
GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS
5723PDF: 1084HTML: 482TABLE: 221FIGURES: 297 -
-
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
4074PDF: 1192HTML: 472 -
HEMATOPOIETIC STEM CELL TRNSPLANTATION IN THALASSEMIA AND RELATED DISORDERS
1959PDF: 516HTML: 4046 -
-
A A RETROSPECTIVE LONG-TERM STUDY ON AGE AT MENARCHE AND MENSTRUAL CHARACTERISTICS IN 85 YOUNG WOMEN WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (TDT) BORN BETWEEN 1965 AND 1995 Long-Term Study on Age at Menarche and Menstrual Characteristics in patients with TDT
1662PDF: 552HTML: 271 -
PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?
3017PDF: 1022HTML: 2119Cover letter: 207 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2096PDF: 1686HTML: 807 -
Should every patient with MDS get iron chelation – probably yes.
2400PDF: 1000HTML: 398 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4406PDF: 1579HTML: 473 -
-
PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.
3247PDF: 1361HTML: 11862 -
ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS
3003PDF: 1017HTML: 7502 -
AGING WITH THALASSEMIA AND SICKLE CELL DISEASE: A GERONTOLOGICAL MODEL OF ACCELERATED MULTIMORBIDITY AND FUNCTION-CENTERED CARE BEYOND MIDLIFE Thalassemia and Sickle Cell Diseases: Effect of Aging
562PDF: 595Suppl. Files: 76HTML: 164







